<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03454945</url>
  </required_header>
  <id_info>
    <org_study_id>doxycycline</org_study_id>
    <nct_id>NCT03454945</nct_id>
  </id_info>
  <brief_title>Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides</brief_title>
  <official_title>Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current study aims at assessing the efficacy of doxycycline as a potential treatment modality
      for early stages of MF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

      Objective is to evaluate the efficacy of doxycycline in treatment of early stages of mycosis
      fungoides (IA, IB and IIA) and to assess its apoptotic enhancing effect by studying the
      expression of BCL2 by the T lymphocytes.

      Study Design

      Randomized controlled trial

      Population of study &amp; disease condition

      30 patients with early stage mycosis fungoides (Stage Ia,Ib and IIa)

      Methodology in details

      After signing an informed consent, each participant will be subjected to:

      I. Baseline evaluation:

        1. Baseline biopsy to document the current state of the disease and to assess
           immunohistochemically the expression of CD3 and Bcl2 by the lymphocytes.

        2. Detailed history taking including onset, course, duration of the disease and history of
           any previous treatments used.

        3. Detailed examination of skin lesions and scoring using:

             -  Modified Severity of Index Weighted Assessment (mSWAT)

             -  Composite Assessment of Index Lesion Severity (CAILS)

        4. Pruritus scoring using a visual analog scale from 0-10, where 0=no pruritus and 10=worst
           imaginable pruritus

        5. Photography

      II. Treatment and dosing protocol:

      Participants will be randomly allocated in either one of the treatment groups:

      Group A: Will receive oral doxycycline in a dose of 200 mg daily for three months.

      Group B: Will receive PUVA with dosing &amp; increments according to the standard protocols of
      the Phototherapy Unit, Dermatology Department, Cairo University; 3 sessions per week for 3
      months.

      III. Timings of follow up visits and clinical assessments done:

      Patients will be regularly assessed at weeks 4, 8, and 12. Patients continuing for another
      three months, as mentioned above, will be assessed at weeks 16, 20 and 24. The following will
      be done at these follow up visits: mSWAT, CAILS, pruritus scoring and photography. Side
      effects will be monitored and managed accordingly.

      IV. Follow up biopsies:

      A repeat biopsy will be taken at initial improvement in CAILS (or at week 12) for
      immunohistochemical re-assessment of the expression of CD3 and Bcl2 by the lymphocytes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical assessment</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical assessment of the extent of the lesions in body surface area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological assessment</measure>
    <time_frame>3months</time_frame>
    <description>Pathological assessment using immunohistochemistry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Doxycyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phototherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UVA+ psoralen 3 sessions per week for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vibramycin</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Doxycyline</arm_group_label>
    <arm_group_label>Phototherapy</arm_group_label>
    <other_name>Doxy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phototherapy</intervention_name>
    <description>UVA+Psoralen</description>
    <arm_group_label>Doxycyline</arm_group_label>
    <arm_group_label>Phototherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (above 18) of either sex with established diagnosis of classic MF

        Exclusion Criteria:

          -  Any variant of MF other than the classic variant.

          -  Advanced stages of classic MF: Stage IIb, III or IV.

          -  Pregnant and lactating females.

          -  Patients with autoimmune diseases e.g. SLE

          -  Patients with solid or hematological malignancies e.g. breast cancer, leukemia, etc.

          -  Patients with any contraindications for doxycycline (eg: liver disease, kidney
             disease, photosensitivity, peptic ulcer or patients receiving systemic retinoids).

          -  Patients with any contraindication to phototherapy (eg: any other skin cancers or
             photosensitivity); or to psoralen (eg: liver disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona AbdEl Halim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hagar El Sayed, Master</last_name>
    <phone>01061248365</phone>
    <email>hgr_ntr@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzan Shalaby, MD</last_name>
    <phone>01224019459</phone>
    <email>suzyandnls@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dermatology departement</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagar El Sayed, MD</last_name>
      <phone>01051248365</phone>
      <email>hgr_ntr@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Suzan Shalaby, MD</last_name>
      <phone>01224019459</phone>
      <email>suzyandnls@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dermatology department</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagar El Sayed, Master</last_name>
      <phone>01061248365</phone>
      <email>hgr_ntr@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Suzan Shalaby, MD</last_name>
      <phone>01224019459</phone>
      <email>suzyandnls@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hagar El Sayed</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Mycosis fungoides</keyword>
  <keyword>Doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

